Aqueous Extract of Brassica rapa Exerts Antihyperglycemic Activity in Streptozotocin-induced Diabetic Rats

Cardiovasc Hematol Disord Drug Targets. 2021;21(4):253-259. doi: 10.2174/1871529X21666211209114436.

Abstract

Aims: The aim of the study was to assess the antihyperglycemic effect of Brassica rapa.

Background: Brassica rapa (turnip) is used as an antidiabetic plant.

Objective: This work aimed to evaluate the effect of the aqueous extract of Brassica rapa seeds (AEBRS) on glycemia in vivo.

Methods: The effect of AEBRS (60 mg/kg) on glycemia and lipid profiles was evaluated. Besides, preliminary phytochemical analysis and the in vitro antioxidant effect were evaluated.

Results: AEBRS caused a significant reduction in blood glucose levels in diabetic rats (p<0.0001). In contrast, no significant effect was observed on lipid profiles, whereas antioxidant potential of this extract has been shown. Phytochemical analysis showed the presence of many important phytochemical families.

Conclusion: The present study shows that AEBRS has a potent antihyperglycemic ability in diabetic rats.

Keywords: Brassica rapa seeds; antidiabetic; antioxidant activity.; medicinal plant; phytochemistry; streptozotocin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose
  • Brassica rapa*
  • Diabetes Mellitus, Experimental* / drug therapy
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Rats
  • Rats, Wistar
  • Streptozocin

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Plant Extracts
  • Streptozocin

Grants and funding